Market Overview

Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product

Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product
The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings
Catalyst Biosciences Shares Volatile On Positive Late-Stage Hemophilia Trial Results

Catalyst Biosciences Inc (NASDAQ: CBIO), a nano-cap clinical-stage biopharmaceutical company that focuses on the treatment of hemophilia, has high expectations for its therapy for the treatment of hemophilia B.

The Analyst

Chardan's Gbola Amusa maintains a Buy rating on Catalyst Biosciences' stock with a price target boosted from $10 to $75.

The Thesis

Catalyst demonstrated the true potential of its hemophilia B therapy, CB 2679d/ISU304, to become not only the first subcutaneously-delivered factor IX product in hemophilia B, but also a better overall product, Amusa said in a note. Specifically, the company's presentations at the European Association for Haemophilia and Allied Disorders (EAHAD) detailed how its therapy is 22 times more potent than the current standard care, BeneFIX.

The company also reported a "moderate generalized ache and mild subcutaneous (SQ) injection site discomfort in one subject and a brief mild adverse event among two other subjects, the analyst wrote.

The analyst's $65 per share price target boost is based on the fact that credible comparisons in the hemophilia B market trade at a minimum market capitalization of $500 million to $600 million versus its $151 million valuation as of Friday morning.

Price Action

Shares of Catalyst Biosciences were trading lower by 4 percent at $26.24 Friday.

Related Links:

19 Biotech Stocks With Clinical Trial Outcomes In February

The Companies That Led 2017's Biotech Rally

Latest Ratings for CBIO

Jun 2018B. Riley FBRDowngradesBuyNeutral
Feb 2018B. Riley FBRMaintainsBuyBuy
Feb 2018Chardan CapitalMaintainsBuyBuy

View More Analyst Ratings for CBIO
View the Latest Analyst Ratings

Posted-In: Chardan Gbola Amusa HemophiliaAnalyst Color Biotech Price Target Analyst Ratings General Best of Benzinga


Related Articles (CBIO)

View Comments and Join the Discussion!

Latest Ratings

TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
BCOVB. Riley FBRUpgrades12.0
CAMPFirst AnalysisDowngrades22.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Monmouth Real Estate To Experience Slower External Growth, Says B Riley FBR

Helios And Matheson CEO: MoviePass Open To Netflix, Amazon Prime Partnerships